Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2240 - 5-ALA administration for photodynamic diagnosis of peritoneal metastases due to advanced gastric cancer: A randomised, double-blind, multicentre phase I/II study


11 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Cancer Diagnostics;  Translational Research;  Gastric Cancer


Tsuyoshi Takahashi


Annals of Oncology (2017) 28 (suppl_5): v449-v452. 10.1093/annonc/mdx378


T. Takahashi1, K. Fujitani2, T. Omori3, K. Nishikawa4, T. Hayashi5, T. Namikawa6, E. Otsuji7, S. Takiguchi8, Y. Doki1

Author affiliations

  • 1 Department Of Gatroenterological Surgery, Osaka university hospoital, 5650871 - Suita/JP
  • 2 Department Of Surgery, Osaka General Medical Center, 558-8558 - Osaka/JP
  • 3 Department Of Surgery, Osaka International Cancer Institute, osaka/JP
  • 4 Surgery, National Hospital Organization Osaka National Hospital, 540-0006 - Osaka/JP
  • 5 Surgery, Saito yukoukai hospital, ibaraki/JP
  • 6 Surgery, Kochi university hospital, Nankoku/JP
  • 7 Surgery, Kyoto prefectural university hospital, Kyoto/JP
  • 8 Surgery, Nagoya city university hospital, Nagoya/JP


Abstract 2240


For advanced gastric cancer, diagnosis of peritoneal dissemination is mandatory prior to the decision of therapy; therefore, staging laparoscopy (SL) has gained wider clinical acceptance. We have reported the efficacy of SL with photodynamic diagnosis (PDD) using 5-aminolevulinic acid (5-ALA). In this study, the safety and effectiveness of oral administration of 5-ALA PDD compared with that of conventional white-light laparoscopic diagnosis is assessed in a phase I/II study. This research also used a randomised double-blind comparison to explore the optimum dose of 5-ALA to be followed by a confirmatory study.


Subjects were patients with type 3 or 4 gastric cancer. A total of 20 or 40 mg/kg 5-ALA was administered orally 180–300 minutes before SL. The primary endpoint was safety; the secondary endpoints were sensitivity, specificity, positive predictive value, negative predictive value, and the proportion of patients with peritoneal dissemination.


Thirty-one patients, comprising 19 men and 12 women, were enrolled. Fourteen patients were allocated to the 20 mg/kg group and 17 to the 40 mg/kg group. The median age was 70 years. The proportions of adverse events were 53.8% and 41.2% in the 20 and 40 mg/kg groups, respectively. Hypotension was noted as serious adverse event in 1 patient. The sensitivities of PDD in the 20 and 40 mg/kg groups were higher (95.7% and 100%, respectively) than those of conventional diagnosis (73.9% and 67.8%) (p = 0.0625 and p = 0.0313). In terms of precision, the evaluation values of diagnosis through conventional imaging compared with PDD were as follows: sensitivity, 83.5% vs. 98.6%; specificity, 75.5% vs. 38.8%; positive predictive value, 82.2% vs. 69.6%; and negative predictive value, 75.5% vs. 95.0%, respectively. In addition, one more patient was found positive for dissemination via PDD.


This investigator-initiated clinical trial confirmed the safety and effectiveness of 5-ALA administration in PDD for peritoneal metastases in gastric cancer. Results indicated that both doses of 5-ALA may be clinically applicable. Thus, we are now conducting a confirmatory study to apply for pharmaceutical approval of 5-ALA.

Clinical trial identification


Legal entity responsible for the study

Prof. Yuichiro Doki


This work was supported by the clinical trial promotion pro-gram subsidized by the Japan Medical Association with theMinistry of Health, Labour and Welfare Research Grant


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.